NCT04049045 - Effects of Empagliflozin on Diuresis and Renal Function in Patients With Acute Decompensated Heart Failure | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 29, 2019

Primary Completion Date

May 30, 2021

Study Completion Date

June 29, 2021

Conditions

Acute Decompensated Heart Failure

Interventions

DRUG

Empagliflozin 25 mg

Empagliflozin 25 mg film-coated tablets, for oral use administered once daily for 5 days in addition to routinely administered (weight adjusted) intravenous furosemide

DRUG

Placebo

matching Placebo, film-coated tablets, for oral use, matching to investigational product Jardiance® administered once daily for 5 days in addition to routinely administered (weight adjusted) intravenous furosemide

Trial Locations (1)

07747

Department of Internal Medicine I, Jena University Hospital, Jena